Pharmaceutical Company
Issues generally related to:  bio-pharmaceutical drugs and drug development programs, including but not limited to Orphan Drug Act incentives, the 340B program, drug pricing proposals, and FDA approvals of drugs designed to treat rare diseases. Issues generally related to:  bio-pharmaceutical drugs and drug development programs, including but not limited to Orphan Drug Act incentives, the 340B program, drug pricing proposals, and FDA approvals of drugs designed to treat rare diseases. Bio-pharmaceutical drugs & drug development programs, particularly those designed to treat rare diseases, such as Orphan Drug Act Incentives, Medicare & Medicaid access, charitable foundations for co-pay assistance, and newborn screening. Bio-pharmaceutical drugs & drug development programs; particularly those designed to treat rare diseases, such as Orphan Drug Act Incentives, Medicare & Medicaid access, charitable foundations for co-pay assistance, and newborn screening.
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations TAX - Taxation/Internal Revenue Code
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CHAMBER HILL STRATEGIES
3325 N Kensington Street, Arlington, VA, 22207, US
MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN
Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce